Skip to main content
SpringerLink
Log in

Prostate Cancer

  • Chapter
Radiation Oncology

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

Abstract

Prostate cancer is the most prevalent cancer and is the second most common cause of cancer death in American men (Jemal et al. 2007). In the era or PSA screening, the majority of patients are diagnosed prior to the onset of the symptoms. According to the pre-treatment PSA, tumor differentiation (Gleason score) and stage, prostate cancer can be categorized into different risk groups, which can assist in determining treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allaf ME, Palapattu GS, Trock BJ et al. (2004) Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172:1840–1844

    Article  PubMed  Google Scholar 

  • Allsbrook WC Jr, Mangold KA, Johnson MH et al. (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 32:74–80

    Article  PubMed  Google Scholar 

  • Arcangeli CG, Humphrey PA, Smith DS et al. (1998) Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 51:558–564

    Article  PubMed  CAS  Google Scholar 

  • Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984

    Article  PubMed  CAS  Google Scholar 

  • Bolla M, Collette L, Blank L et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106

    Article  PubMed  CAS  Google Scholar 

  • Bolla M, van Poppel H, Collette L et al. (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572–578

    Article  PubMed  Google Scholar 

  • Beyer DC, Thomas T, Hilbe J et al. (2003) Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2:77–84

    Article  PubMed  Google Scholar 

  • Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095–1101

    Article  PubMed  CAS  Google Scholar 

  • Brenner DJ, Martinez AA, Edmundson GK et al. (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6–13

    PubMed  Google Scholar 

  • Carroll P, Coley C, McLeod D et al. (2001) Prostate-specific antigen best practice policy-part II: prostate cancer staging and post-treatment follow-up. Urology 57:225–229

    Article  PubMed  CAS  Google Scholar 

  • Corn BW, Winter K, Pilepich MV (1999) Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. Urology 54:495–502

    Article  PubMed  CAS  Google Scholar 

  • Crook J, Milosevic M, Catton P et al. (2002) Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. Brachytherapy 1:66–73

    Article  PubMed  Google Scholar 

  • Crook J, Ludgate C, Malone S et al. (2004) Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60:15–23

    Article  PubMed  Google Scholar 

  • Crook JM, Potters L, Stock RG et al. (2005) Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy 4:186–194

    Article  PubMed  Google Scholar 

  • D’Amico AV, Whittington R, Malkowicz SB et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

    Article  PubMed  CAS  Google Scholar 

  • D’Amico AV, Whittington R, Malkowicz SB et al. (1999) Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17:168–172

    PubMed  CAS  Google Scholar 

  • D’Amico AV, Cote K, Loffredo M et al. (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20:4567–4573

    Article  PubMed  Google Scholar 

  • D’Amico AV, Keshaviah A, Manola J et al. (2002) Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 53:581–587

    PubMed  Google Scholar 

  • D’Amico AV, Chen MH, Roehl KA et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351(2):125–135

    Article  PubMed  CAS  Google Scholar 

  • D’Amico AV, Manola J, Loffredo M et al. (2004) Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:821–827

    Article  PubMed  CAS  Google Scholar 

  • D’Amico AV, Chen MH, Renshaw AA et al. (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299:289–295

    Article  PubMed  CAS  Google Scholar 

  • Dearnaley DP, Sydes MR, Graham JD et al. (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475–487

    Article  PubMed  Google Scholar 

  • Demanes DJ, Rodriguez RR, Schour L et al. (2005) Highdose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61:1306–1316

    PubMed  Google Scholar 

  • Denham JW, Steigler A, Lamb DS et al. (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841–850

    Article  PubMed  CAS  Google Scholar 

  • Fowler J, Chappell R, Ritter M. (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021–1031

    Article  PubMed  CAS  Google Scholar 

  • Granfors t, Modig H, Damber JE et al. (2006) Long-term follow-up of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 176:544–547

    Article  PubMed  Google Scholar 

  • Grimm PD, Blasko JC, Sylvester JE et al. (2001) 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51:31–40

    PubMed  CAS  Google Scholar 

  • Han M, Partin AW, Pound CR et al. (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565

    Article  PubMed  CAS  Google Scholar 

  • Hanks GE, Hanlon AL, Epstein B et al. (2002) Dose response in prostate cancer with 8–12 years’ follow-up. Int J Radiat Oncol Biol Phys 54:427–435

    PubMed  Google Scholar 

  • Hanks GE, Pajak TF, Porter A et al. (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972–3978

    Article  PubMed  CAS  Google Scholar 

  • Hull GW, Rabbani F, Abbas F et al. (2002) Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167:528–534

    Article  PubMed  Google Scholar 

  • Hayes SB, Pollack A (2005) Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol 23:8204–8211

    Article  PubMed  Google Scholar 

  • Holmberg L, Bill-Axelson A, Helgesen F et al. (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781–789

    Article  PubMed  Google Scholar 

  • Hsu IC, Cabrera AR, Weinberg V et al. (2005) Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy. 4:202–206

    Article  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66

    Article  PubMed  Google Scholar 

  • Kattan MW, Zelefsky MJ, Kupelian PA et al. (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352–3359

    PubMed  CAS  Google Scholar 

  • Kattan MW, Potters L, Blasko JC et al. (2001) Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58:393–399

    Article  PubMed  CAS  Google Scholar 

  • Kattan MW, Zelefsky MJ, Kupelian PA et al. (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21:4568–4571

    Article  PubMed  Google Scholar 

  • King CR, Fowler JF (2001) A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51:213–214

    PubMed  CAS  Google Scholar 

  • King CR, Spiotto MT (2008) Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 71:23–27

    PubMed  Google Scholar 

  • Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172:S48–50

    Article  PubMed  Google Scholar 

  • Kuban DA, Tucker SL, Dong L et al. (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74

    PubMed  Google Scholar 

  • Kupelian P, Kuban D, Thames H et al. (2005) Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61:415–419

    PubMed  Google Scholar 

  • Kupelian PA, Potters L, Khuntia D et al. (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33

    Article  PubMed  Google Scholar 

  • Kupelian PA, Willoughby TR, Reddy CA et al. (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68:1424–1430

    PubMed  Google Scholar 

  • Lattanzi J, McNeeley S, Pinover W et al. (1999) A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys 43:719–725

    PubMed  CAS  Google Scholar 

  • Laverdiere J, Nabid A, De Bedoya LD et al. (2004) The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171:1137–1140

    Article  PubMed  CAS  Google Scholar 

  • Lawton CA, DeSilvio M, Roach M 3rd et al. (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646–655

    PubMed  Google Scholar 

  • Lawton CA, Winter K, Murray K et al. (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937–946

    Article  PubMed  CAS  Google Scholar 

  • Madsen BL, Hsi RA, Pham HT et al. (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67:1099–1105

    PubMed  Google Scholar 

  • Martin JM, Rosewall T, Bayley A et al. (2007) Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69:1084–1089

    PubMed  Google Scholar 

  • Moseley DJ, White EA, Wiltshire KL et al. (2007) Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for online image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 67:942–953

    PubMed  Google Scholar 

  • Nag S, Beyer D, Friedland J et al. (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44:789–799

    Article  PubMed  CAS  Google Scholar 

  • Partin AW, Mangold LA, Lamm DM et al. (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843–848

    Article  PubMed  CAS  Google Scholar 

  • Peeters ST, Heemsbergen WD, Koper PC et al. (2006) Dose response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996

    Article  PubMed  Google Scholar 

  • Pilepich MV, Winter K, John MJ et al. (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243–1252

    PubMed  CAS  Google Scholar 

  • Pollack A, Hanlon AL, Horwitz EM et al. (2004) Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol 171:1132–1136

    Article  PubMed  Google Scholar 

  • Pollack A, Zagars GK, Starkschall G et al. (2002) Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105

    Article  PubMed  Google Scholar 

  • Pollack A, Hanlon AL, Horwitz EM et al. (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64:518–526

    PubMed  Google Scholar 

  • Pommier P, Chabaud S, Lagrange JL et al. (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366–5373

    Article  PubMed  Google Scholar 

  • Pouliot J, Aubin M, Langen KM et al. (2003) (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 56:862–866

    PubMed  Google Scholar 

  • Rajesh A, Coakley FV, Kurhanewicz J (2007) 3D MR spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol 62:921–929

    Article  PubMed  CAS  Google Scholar 

  • Rivard MJ, Butler WM, Devlin PM et al. (2007) American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 6:34–37

    Article  PubMed  Google Scholar 

  • Roach M (1993) Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:1923–1924

    PubMed  Google Scholar 

  • Roach M, Lu J, Pilepich MV et al. (2000) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47:609–615

    Article  PubMed  CAS  Google Scholar 

  • Roach M, DeSilvio M, Lawton C et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911

    Article  PubMed  Google Scholar 

  • Roach M, DeSilvio M, Valicenti R et al. (2006) Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66:647–653

    PubMed  Google Scholar 

  • Roach M 3rd, Hanks G, Thames H Jr et al. (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974

    PubMed  Google Scholar 

  • Roehl KA, Han M, Ramos CG et al. (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910–914

    Article  PubMed  Google Scholar 

  • Schiffner DC, Gottschalk AR, Lometti M et al. (2007) Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys 67:610–619

    PubMed  Google Scholar 

  • Shih HA, Harisinghani M, Zietman AL et al. (2005) Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 63:1262–1269

    PubMed  Google Scholar 

  • Spiotto MT, Hancock SL, King CR (2007) Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69:54–61

    PubMed  Google Scholar 

  • Stephenson AJ, Scardino PT, Kattan MW et al. (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041

    Article  PubMed  Google Scholar 

  • Stock RG, Stone NN, Dahlal M et al. (2002) What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy 1:83–89

    Article  PubMed  Google Scholar 

  • Swanson GP, Hussey MA, Tangen CM et al. (2007) Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25:2225–2229

    Article  PubMed  Google Scholar 

  • Sylvester JE, Blasko JC, Grimm PD et al. (2003) Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 57:944–952

    PubMed  Google Scholar 

  • Sylvester JE, Grimm PD, Blasko JC et al. (2007) Fifteen-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67:57–64

    PubMed  Google Scholar 

  • Thompson IM, Tangen CM, Paradelo J et al. (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:2329–2335

    Article  PubMed  CAS  Google Scholar 

  • Van der Kwast Bolla M Van Poppel H et al. 2007 Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy EORTC 22911. J Clin Oncol 254178–4186

    Google Scholar 

  • Vargas CE, Martinez AA, Boike TP et al. (2006) High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys 66:416–423

    PubMed  Google Scholar 

  • Wiegel T, Willich N, Piechota H et al. (2005) Phase III results of adjuvant radiotherapy (RT) versus “wait and see” (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP). J Clin Oncol 23(Suppl):4513

    Google Scholar 

  • Wang-Chesebro A, Xia P, Coleman J et al. (2006) Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66:654–662

    PubMed  Google Scholar 

  • Zelefsky MJ, Fuks Z, Hunt M et al. (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876–881

    Article  PubMed  CAS  Google Scholar 

  • Zelefsky MJ, Chan H, Hunt M et al. (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urology 176:1415–1419

    Article  Google Scholar 

  • Zelefsky MJ, Kuban DA, Levy LB et al. (2007) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327–333

    PubMed  Google Scholar 

  • Zelefsky MJ, Yamada Y, Cohen GN et al. (2007) Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 67:65–70

    PubMed  Google Scholar 

  • Zhang JQ, Loughlin KR, Zou KH et al. (2007) Role of endorectal coil magnetic resonance imaging in treatment of patients with prostate cancer and in determining radical prostatectomy surgical margin status: report of a single surgeon’s practice. Urology 69:1134–1137

    Article  PubMed  Google Scholar 

  • Zietman AL, DeSilvio ML, Slater JD et al. (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294:1233–1239

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, National University Cancer Institute of Singapore, National University Health System, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore

    Hans T. Chung MD, FRCPC

Authors
  1. Hans T. Chung MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology National University Cancer Institute of Singapore National University Health System, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore

    Jiade J. Lu MD, MBA (Associate Professor and Consultant and Distinguished Clinical Professor) (Associate Professor and Consultant and Distinguished Clinical Professor)

  2. Department of Radiation Oncology, Cancer Hospital of Fudan University, 270 Dong An Road, Shanghai, 200232, P.R. China

    Jiade J. Lu MD, MBA (Associate Professor and Consultant and Distinguished Clinical Professor) (Associate Professor and Consultant and Distinguished Clinical Professor)

  3. College of Medicine, Drexel University, Broad & Vine Sts., Mail Stop 200, Philadelphia, PA, 19102-1192, USA

    Luther W. Brady MD (Hylda Cohn/American Cancer Society Professor of Clinical Oncology, and Professor, Department of Radiation Oncology Distinguished University Professor) (Hylda Cohn/American Cancer Society Professor of Clinical Oncology, and Professor, Department of Radiation Oncology Distinguished University Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Chung, H.T. (2008). Prostate Cancer. In: Lu, J.J., Brady, L.W. (eds) Radiation Oncology. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77385-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-77385-6_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-77384-9

  • Online ISBN: 978-3-540-77385-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation